A new study reveals that metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is on track to impact nearly 1.8 billion individuals worldwide by the year 2050. Currently, the condition affects approximately 1.3 billion people globally, which equates to about one in six individuals, and its prevalence is expected to rise significantly due to increasing rates of obesity and high blood sugar levels.
Rising Prevalence of MASLD
Research published in the *Lancet Gastroenterology & Hepatology* journal indicates that MASLD has become one of the most common and rapidly escalating liver diseases across the globe. The study, part of the global burden of diseases, injuries, and risk factors project, highlights a staggering 143% increase in cases over the past 30 years. In 1990, around 500 million people were diagnosed with MASLD; this figure has surged to 1.3 billion by 2023, with projections suggesting a further 42% rise by 2050.
The global prevalence of MASLD now stands at approximately 14,429 cases per 100,000 individuals, marking a 29% increase since 1990. The condition is more frequently observed in men than in women, with the highest rates found among older adults aged 80 to 84. However, younger demographics, particularly men aged 35 to 39 and women aged 55 to 59, represent the largest number of cases.
Key Risk Factors
The findings underscore that high blood sugar levels are the primary contributor to MASLD-related health issues, closely followed by elevated body mass index (BMI) and smoking. These risk factors highlight strong associations with type 2 diabetes and obesity, conditions that are becoming increasingly prevalent worldwide.
Certain regions are experiencing disproportionately high rates of MASLD. For instance, North Africa and the Middle East report particularly striking figures. In the UK, the prevalence has risen by 33% since 1990, marking the largest increase in Western Europe. Other countries, such as Australia and the United States, have also seen significant rises of 30% and 22%, respectively.
Health Impact and Future Concerns
Interestingly, while the number of individuals developing the disease continues to grow, the overall impact on health—measured in years lost due to illness or premature death—has remained stable. This stability suggests that advancements in treatment and healthcare are enabling individuals with MASLD to live longer, healthier lives, with many cases being diagnosed in their early stages.
Despite this encouraging trend, the escalating number of cases raises concerns about the potential for serious complications in the future, such as liver cirrhosis or cancer. MASLD often goes unnoticed, as it typically presents no symptoms until it has progressed significantly. Individuals may experience fatigue, general malaise, or discomfort in the abdomen, usually on the right side beneath the ribs, but these symptoms are often mistaken for other ailments.
A Call to Action
Led by the Institute for Health Metrics and Evaluation at the University of Washington, the study’s authors stress the urgent need for increased awareness and intervention regarding MASLD. With the condition increasingly affecting younger adults amid deteriorating health and lifestyle choices, it is crucial to establish policies and awareness campaigns aimed at mitigating its impact and preventing future health complications.
Why it Matters
The projected rise in MASLD cases highlights a significant public health challenge that requires immediate attention. As obesity and metabolic disorders become more prevalent, understanding and addressing MASLD is crucial for safeguarding the future health of millions worldwide. By prioritising early detection, lifestyle interventions, and comprehensive healthcare strategies, we can work towards reducing the burdens associated with this condition and improving overall health outcomes for affected individuals.
